Showing results (161-170 of 205) with videos related to
Sort By:
Pageof 21
Science Signaling|December 5, 2013
PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic KrasErnesto Diaz-Flores, Hana Goldschmidt, Philippe Depeille, et al.Blood|March 29, 2020
Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in miceNoemi A Zambetti, Ari J Firestone, Jarrett R Remsberg, et al.Journal of the National Cancer Institute|September 7, 2021
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase InhibitorsKelly L Schoenbeck, Ehab Atallah, Li Lin, et al.Cancer Discovery|June 13, 2024
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology GroupElliot Stieglitz, Alex G Lee, Steven P Angus, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2008
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemiaNeil P Shah, Hagop M Kantarjian, Dong-Wook Kim, et al.Cell Reports|February 9, 2016
KRAS Engages AGO2 to Enhance Cellular TransformationSunita Shankar, Sethuramasundaram Pitchiaya, Rohit Malik, et al.Biorxiv : the Preprint Server for Biology|April 8, 2025
TP53 Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid LeukemiaJeevitha D'Souza, Camille J Leung, Aishwarya C Ballapuram, et al.Elife|July 21, 2015
Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesisJasmine C Wong, Kelley M Weinfurtner, Maria Del Pilar Alzamora, et al.Science Signaling|March 28, 2013
Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesisCatherine Hartzell, Olga Ksionda, Ed Lemmens, et al.Blood|November 15, 2007
Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology groupBeverly J Lange, Franklin O Smith, James Feusner, et al.Pageof 21